Community pharmacy and pharmacist staff call center: assessment of medication safety and effectiveness.
OBJECTIVE
To determine proof of concept for use of a network of pharmacists to evaluate the safety of medications.


METHODS
Pilot, comparative, prospective evaluation.


METHODS
Community pharmacies and a pharmacist-staffed call center in Arizona during January through August 2006.


METHODS
Patients filling prescriptions for ipratropium or tiotropium bromide at 1 of 55 Arizona pharmacies were encouraged to call a pharmacist-staffed call center. A total of 67 patients contacted the center and 41 participated.


METHODS
A network of community pharmacies and a call center were used to collect data on patients receiving one of two medications for the treatment of chronic obstructive pulmonary disease. Pharmacists in the community pharmacies recruited patients who presented with a prescription or requested a refill for one of the medications. The call center was used to collect patient data. Patients provided data on medication use, completed the chronic respiratory questionnaire (CRQ), and were encouraged to call the center to report health problems. After 30 days, patients were called to determine whether they experienced any adverse events while taking their medication and the CRQ was readministered.


METHODS
Knowledge gained on the feasibility of the model using pharmacists to assess drug safety.


RESULTS
A total of 67 (6.7%) of a possible 995 patients contacted the call center about participating in the study. Approximately one-half (n = 28) of the 55 pharmacies had one or more patients contact the center about the study. A total of 41 patients met inclusion/exclusion criteria and were enrolled. Six (15%) patients reported an adverse effect, including one serious adverse event (acute glaucoma).


CONCLUSIONS
This study provides limited evidence that community pharmacies and a pharmacist-staffed call center can be used to assess medication safety; however, a number of issues need to be examined to determine whether the approaches can be sufficiently effective.
Critical Path Institute, Tucson, AZ 85721-0202, USA.
Lisa
L
Higgins
Mary
M
Brown
John E
JE
Murphy
Daniel C
DC
Malone
Edward P
EP
Armstrong
Raymond L
RL
Woosley
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001130:Arizona; D001993:Bronchodilator Agents / Q000009:adverse effects / Q000627:therapeutic use; D003157:Community Pharmacy Services; D016903:Drug Monitoring / Q000379:methods*; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D009241:Ipratropium / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010595:Pharmacists; D010865:Pilot Projects; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy; D012602:Scopolamine Derivatives / Q000009:adverse effects / Q000627:therapeutic use; D013689:Telephone; D000069447:Tiotropium Bromide
D001993:Bronchodilator Agents; D012602:Scopolamine Derivatives; D009241:Ipratropium; D000069447:Tiotropium Bromide